Nanosonics Appoints Michael Kavanagh as CEO and President and Dr. Ron Weinberger as President Technology Development/Commercialisation
8/28/2013 8:53:14 AM
Nanosonics appoints Michael Kavanagh as CEO and President and Dr. Ron Weinberger as President Technology Development / Commercialisation
28 August 2013 -- Nanosonics Limited (ASX: NAN) is pleased to announce the appointment of non- Executive Director, Mr Michael Kavanagh as CEO and President effective 21st October
2013. Dr. Ron Weinberger is appointed to the newly created office of President Technology Development / Commercialisation. Both positions will serve on the Board of Directors of Nanosonics. "These new strategic appointments will lead Nanosonics through its next phase of growth and reflect the strategic importance of our expansion initiative to establish Nanosonics as a global leader in advanced microbial control technologies" said Nanosonics Chairman Maurie Stang.
"Michael joined the Nanosonics Board in July 2012 and in that time has made a significant contribution to the overall strategic growth agenda for the organisation" said Maurie Stang. Michael has over 20 years of international commercial experience in
the healthcare market having held local, regional and global roles in Medical Device
and Pharmaceutical industries. Michael holds a BSc Degree from University College Dublin and an MBA (Advanced) from the University of Queensland. Michael is currently the Senior Vice President of Global Marketing for Cochlear Limited, an executive position he has held for the last 10 years.
"I am excited to lead the Nanosonics team through its next phase of growth as CEO and President" said Michael. "The last 12 months as a non-Executive Director has afforded me the opportunity to get to know the business, the talent and commitment of the team that's in place and the nature of the global opportunity for the organisation. Infection control is extremely important on the global health care agenda providing Nanosonics significant growth opportunities through its innovative infection control platform technology".
"Central to the growth strategy is the development and commercialisation of a highly innovative portfolio of technologies based on our core IP and disinfection platform. To lead this effort Dr. Ron Weinberger will take the newly created office of President Technology Development / Commercialisation" said Maurie Stang. Ron will partner closely with Michael and the Board in steering the organisation through its next phase of growth leveraging his extensive experience and knowledge of the infection control marketplace plus the major contributions he has made to Nanosonics to date.
"This is an exciting time for Nanosonics as we begin to realise our true global potential" said Ron. "Over the last 12 months I have worked closely with Michael in his role on the Board and look forward to partnering with him in leading the organisation through
its next phase of growth and establishing our advanced microbial control technologies
as the new standard of care".
Maurie Stang Chairman For more information please contact:
Maurie Stang, Chairman on 02 9381 1005
Rebecca Wilson, Investor and media relations, Buchan Consulting on (03) 9866 4722 /
Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets.
Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries.
Help employers find you! Check out all the jobs and post your resume.
comments powered by